PRDO Stock Analysis: Perdoceo Education | NASDAQ
Education & Training Services | NASDAQ, USA | Market Cap: 2.121m USD | 12M Return: -9.9% | US71363P1066 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 18.0M
EPS Trend: 93.9%
Qual. Beats: 0
Rev. Trend: 79.5%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Perdoceo Education Corporation (PRDO) is a U.S.-based provider of postsecondary education operating through online, campus-based, and blended learning formats. The company runs three segments: Colorado Technical University (CTU), the American InterContinental University System (AIUS), and the University of St. Augustine for Health Sciences (USAHS). CTU and AIUS offer career-oriented undergraduate and graduate programs in fields such as business, technology, healthcare management, and behavioral sciences, while USAHS focuses on graduate health sciences degrees in physical therapy, occupational therapy, speech language therapy, and nursing, along with continuing education offerings.
The company also delivers non-degree and professional development programs and supports its instruction with proprietary technology, including the Intellipath learning platform, a mobile application, and a two-way messaging system. Perdoceo was formerly known as Career Education Corporation before adopting its current name in January 2020 and is headquartered in Schaumburg, Illinois.
PRDO operates within the for-profit education services sector, a segment of the broader Consumer Discretionary industry that serves primarily adult and working learners seeking flexible, career-focused credentials. Its multi-brand, multi-modality model - combining online instruction with select campus locations and adaptive learning tools - is characteristic of publicly traded U.S. for-profit education providers that compete with both nonprofit universities and emerging online platforms.
- USAHS health sciences enrollment drives segment revenue growth
- CTU and AIUS new student starts decline pressure total revenue
- Title IV regulation and gainful employment rules remain key risk
| Net Income: 177.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA 0.47 > 1.0 |
| NWC/Revenue: 73.56% < 20% (prev 71.85%; Δ 1.71% < -1%) |
| CFO/TA 0.17 > 3% & CFO 225.4m > Net Income 177.1m |
| Net Debt (-1.30b) to EBITDA (275.4m): -4.71 < 3 |
| Current Ratio: 4.69 > 1.5 & < 3 |
| Outstanding Shares: last quarter (63.6m) vs 12m ago -4.91% < -2% |
| Gross Margin: 71.15% > 18% (prev 78.89%; Δ -7.74% > 0.5%) |
| Asset Turnover: 65.32% > 50% (prev 59.40%; Δ 5.92% > 0%) |
| Interest Coverage Ratio: 38.29 > 6 (EBIT TTM 237.0m / Interest Expense TTM 6.19m) |
| A: 0.47 (Total Current Assets 802.6m - Total Current Liabilities 171.1m) / Total Assets 1.33b |
| B: 0.60 (Retained Earnings 801.0m / Total Assets 1.33b) |
| C: 0.18 (EBIT TTM 237.0m / Avg Total Assets 1.31b) |
| D: 3.43 (Book Value of Equity 1.03b / Total Liabilities 301.1m) |
| Altman-Z'' = 9.88 = AAA |
| DSRI: 0.98 (Receivables 46.5m/42.4m, Revenue 858.6m/768.8m) |
| GMI: 1.11 (GM 78.89% / 71.15%) |
| AQI: 0.92 (AQ_t 0.30 / AQ_t-1 0.33) |
| SGI: 1.12 (Revenue 858.6m / 768.8m) |
| TATA: -0.04 (NI 177.1m - CFO 225.4m) / TA 1.33b) |
| Beneish M = -2.91 (Cap -4..+1) = A |
As of October 27, 2026, the stock is trading at USD 32.71 with a total of 598,162 shares traded. Over the past week, the price has changed by -3.08%, over one month by +9.00%, over three months by +3.65% and over the past year by -9.91%.
Current recommended Stop Loss: 31.60 (which is 3.4% or 1.2 ATR below the current price).
Perdoceo Education has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy PRDO.
- StrongBuy: 0
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 44 | 34.5% |
P/E Trailing = 12.3273
P/E Forward = 10.0705
P/S = 2.4707
P/B = 2.0128
P/EG = 0.6715
Revenue TTM = 858.6m USD
EBIT TTM = 237.0m USD
EBITDA TTM = 275.4m USD
Long Term Debt = 42.4m USD (estimated: total debt 56.6m - short term 14.2m)
Short Term Debt = 14.2m USD (from shortTermDebt, last quarter)
Debt = 170.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 113.8m
Net Debt = -1.30b USD (calculated: Debt 170.4m - CCE 1.47b)
Enterprise Value = 822.9m USD (2.12b + Debt 170.4m - CCE 1.47b)
Interest Coverage Ratio = 38.29 (Ebit TTM 237.0m / Interest Expense TTM 6.19m)
EV/FCF = 3.78x (Enterprise Value 822.9m / FCF TTM 218.0m)
FCF Yield = 26.49% (FCF TTM 218.0m / Enterprise Value 822.9m)
FCF Margin = 25.39% (FCF TTM 218.0m / Revenue TTM 858.6m)
Net Margin = 20.63% (Net Income TTM 177.1m / Revenue TTM 858.6m)
Gross Margin = 71.15% ((Revenue TTM 858.6m - Cost of Revenue TTM 247.7m) / Revenue TTM)
Gross Margin QoQ = 76.15% (prev 74.56%)
Tobins Q-Ratio = 0.62 (Enterprise Value 822.9m / Total Assets 1.33b)
Interest Expense / Debt = 3.63% (Interest Expense 6.19m / Debt 170.4m)
Taxrate = 23.80% (55.3m / 232.4m)
NOPAT = 180.6m (EBIT 237.0m * (1 - 23.80%))
Current Ratio = 4.69 (Total Current Assets 802.6m / Total Current Liabilities 171.1m)
Debt / Equity = 0.16 (Debt 170.4m / totalStockholderEquity, last quarter 1.03b)
Debt / EBITDA = -4.71 (Net Debt -1.30b / EBITDA 275.4m)
Debt / FCF = -5.96 (Net Debt -1.30b / FCF TTM 218.0m)
Total Stockholder Equity = 1.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 13.47% (Net Income 177.1m / Total Assets 1.33b)
RoE = 17.70% (Net Income TTM 177.1m / Total Stockholder Equity 1.00b)
RoCE = 22.72% (EBIT 237.0m / Capital Employed (Equity 1.00b + L.T.Debt 42.4m))
RoIC = 15.92% (NOPAT 180.6m / Invested Capital 1.13b)
WACC = 5.43% (E(2.12b)/V(2.29b) * Re(5.64%) + D(170.4m)/V(2.29b) * Rd(3.63%) * (1-Tc(0.24)))
Discount Rate = 5.64% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -85.75 | Cagr: -2.19%
[DCF] Terminal Value 76.21% ; FCFF base≈212.9m ; Y1≈224.7m ; Y5≈262.8m
[DCF] Fair Price = 85.41 (EV 4.05b - Net Debt -1.30b = Equity 5.34b / Shares 62.6m; r=8.35% [WACC [floored]]; 5y FCF grow 6.13% → 2.50% )
EPS Correlation: 93.93 | EPS CAGR: 13.47% | SUE: 0.0 | # QB: 0
Revenue Correlation: 79.49 | Revenue CAGR: 9.36% | SUE: 0.19 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.74 | Chg30d=+0.00% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=3.13 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+19.9% | GrowthRev=+1.0%
EPS next Year (2027-12-31): EPS=3.30 | Chg30d=+0.00% | Revisions=+25% | GrowthEPS=+5.4% | GrowthRev=+3.0%